Table 2.
Pathohistological changes in kidney of USC-treated rats, compared to those in controls 12 weeks after cell therapy.
| Pathological changes |
PBS-treated Group* |
USC-treated Group* |
Age-matched Control* |
|---|---|---|---|
| n=9 | n=9 | n=10 | |
| Ratio of normal nephrons (%) (Fig. 6) | 38% (4.0±2.0) | 60% (6.33±2.1) | 100% (10.6±2.2) |
| Ratio of abnormal nephrons (%) (Fig. 6) | 62% (6.6±2.0) | 40% (4.27±2.1) | 0% (0.0±0.0) |
| Ratio of collagen deposition (%) ( Fig. 7) | 322% (16.2±4.7) | 152% (7.6±3.3) | 100% (5.0±2.0) |
| Ratio of inflammatory (%) (Fig. 8) | 435% (8.7±2.5) | 235% (4.7±2.1) | 100% (2.0±1.1) |
| Increased interstitial fibrosis (cortex vs. medulla) (%) (Fig. 9) | 158% (1.22±0.1) vs. 182% (1.32±0.08) |
123% (0.95±0.09) vs. 128%(0.99±0.06) |
100% (0.77±0.05) vs. 100%(0.72±0.06) |
Abbreviations: PBS- phosphate buffered saline; USC- urine-derived stem cells.
Notes: Glomerular sclerosis, dilated or atrophic renal tubule structure; Inflammatory response - measured by monocyte infiltration. One-way ANOVA statistical analysis was formed among three groups, based on the average relative intensity of ten fields per sample, each taken at a 200x magnification for immunostaining. Percentages were relative to AMC. All values are reported as mean ± SEM. *All differences listed in this table were statistically significant between the PBS, USC-treated groups, and AMC, p<0.05 or p<0.01.